FemTech

As the FemTech industry experiences significant growth in addressing the needs of women’s health, innovations are rapidly emerging to tackle the gender health gap through advanced technologies and interdisciplinary approaches.

This women-centric focus highlights previously unmet needs and supports the drive for tailored healthcare solutions. However, addressing specific conditions such as menstrual health, reproductive technology, and female oncology presents its challenges, making it imperative to develop culturally sensitive, reliable methods for diverse subpopulations of women, ensuring accessibility and efficacy of emerging technologies.

HGF’s accomplished FemTech team are experts in patent drafting, prosecution, appeals, FTO and infringement opinions, and litigation for large corporate firms, SMEs, universities, and overseas associates. Often working with experts in developmental biology, microbiome technologies, and big data technology companies, our attorneys, with backgrounds in Life Sciences, Chemistry, Electronics, Engineering, and Trade Marks, blend specialist knowledge with critical insights into rapidly evolving FemTech solutions.

We are dedicated to empowering women through innovation, ensuring that intellectual property protection generates new revenue streams, creating substantial business value, and attracting investors.

Latest updates

Event - 2nd June 2026

HGF are proud sponsors of Retail Week General Counsel 2026

HGF is proud to be sponsoring Retail Week General Counsel. This will take place on Wednesday 3rd June at Ham Yard Hotel. The retail legal landscape is undergoing a fundamental …

Event details

AI Governance: In Pursuit of a Rapidly Moving Target

1. Introduction: the governance paradox There is a growing paradox in boardrooms and legal teams: everyone is tired of talking about AI—and yet no one can afford to stop. Artificial …

Read article

Fuelling IP: Green Branding and Trade Mark Risk in the Energy Transition

What do the trade marks GREEN STEAM[1], ECO FLOW[2] and [3] have in common?  The answer is that they are all marks that have been refused by the EU Intellectual …

Read article

Pro = Active? CJEU asked to decide

In a new referral to the EU’s Court of Justice (C-794/25), the CJEU has been asked to rule on the question whether an approved pro-drug of a previously approved active …

Read article

Are Functional Foods ‘Therapeutic’? Insights from the EPO’s Latest Ruling

Abstract: EPO decision T 1396/23 confirms that functional foods can support medical‑use claims when their therapeutic effects are credible, data‑backed, and tied to recognised clinical outcomes. This provides some comfort to …

Read article

The Secrets of MedTech and Digital Health

Protecting hidden value in an era of connected care and intelligent devices With the explosion of AI and machine learning in the MedTech and Digital Health sectors, trade secrets are …

Read article

Santen Revisited – CJEU asked to think again on “first authorisation” for SPCs

A new referral to the Court of Justice of the EU (C-15/26) will once again consider what is meant by the “first marketing authorisation” requirement of Article 3(d) of the …

Read article

PRESS RELEASE - Oliver Pooley joins HGF as a Partner 21st April 2026

HGF is pleased to announce the appointment of Oliver Pooley who will be joining the firm as a Partner on 21st April 2026. Oliver joins our Technology & Engineering Group …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our femtech specialists.